Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00918255 · ClinicalTrials.gov registry record · Phase 2
Study of Adalimumab in Subjects With Moderate to Severe Chronic Hidradenitis Suppurativa
A Phase 2 study, sponsored by Abbott.
- Completed
- Registry status
- Phase 2
- Development phase
- 154
- Enrollment target
NCT00918255 is a Phase 2 study that has completed, run by Abbott. The registered enrollment target is 154 participants.
The verdict
NCT00918255, a Phase 2 study, has completed, sponsored by Abbott.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 154 participants
- Enrollment target
Study Summary
This study will investigate how well adalimumab works in people with hidradenitis suppurativa (HS) in the short and long term.
Interventions
- DRUG Placebo
- BIOLOGICAL adalimumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 154 participants |
| Start Date | 2009-04 |
| Est. Completion | 2010-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00918255
The ClinicalTrials.gov registry entry for NCT00918255 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 154 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Abbott, which has 181 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00918255 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00918255 about?
NCT00918255 is a clinical study titled "Study of Adalimumab in Subjects With Moderate to Severe Chronic Hidradenitis Suppurativa". This study will investigate how well adalimumab works in people with hidradenitis suppurativa (HS) in the short and long term.
What is the current status of trial NCT00918255?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 154 participants. The study started on 2009-04. Estimated completion is 2010-11.
What interventions are being tested in trial NCT00918255?
The interventions under investigation include: Placebo (DRUG), adalimumab (BIOLOGICAL).
Who is sponsoring clinical trial NCT00918255?
This trial is sponsored by Abbott, which has 181 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.